News

Expanding Cas9 Enhances Precision in Base Editing

An American study has explored how enlarging the recognition (REC) domain of CRISPR-Cas9 can improve adenine base editing accuracy. The researchers at Tufts University engineered a “giant” SpCas9 (GS-Cas9) by expanding the REC domain, demonstrating reduced off-target effects and improved precision of the adenine base editor ABE8e.

By: Gorm Palmgren - Mar. 4, 2025
News

The REC domain is a non-catalytic region of Cas9 responsible for DNA recognition and guide RNA (gRNA) interaction. It helps stabilise the RNA-DNA complex and influences the enzyme’s specificity and efficiency. Unlike the RuvC and HNH domains, which cleave DNA, the REC domain ensures proper target alignment.

To construct GS-Cas9, the researchers inserted an extended REC sequence derived from Streptococcus thermophilus Cas9 (St1Cas9) into specific positions within SpCas9’s REC domain. The insertions were linked using flexible peptide sequences from Staphylococcus aureus Cas9 (SaCas9) to maintain structural integrity. The resulting GS-Cas9 had the largest REC domain experimentally characterised to date, expanding from 624 to 1036 amino acids.

The expanded GS-Cas9 maintains on-target editing while significantly reducing unintended modifications. Additionally, the modification regulates the activity of the TadA8e deaminase in ABE8e, lowering RNA off-target effects and improving editing precision.

By demonstrating a method inspired by natural Cas9 evolution, the research suggests that domain expansion can serve as an alternative strategy for enhancing gene editors beyond traditional mutational approaches.

The study was published in Nature Communications on 28 February 2025.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNews

CLINICAL TRIALS
Indicator
IND Enabling
Phase I
Phase II
Phase III
Metastatic Melanoma, (NCT06783270)
Sponsors:
Inge Marie Svane
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06752876)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine